BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT

 
• By Joseph Haas and Sue Sutter

News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies.

Bio 2019 Notebook for Scrip
Merck & Co. exec outlines one proposed "pull incentive" for antibiotic research called the Market Entry Reward. • Source: Shutterstock

More from Cell Therapies

More from Advanced Therapies